Survodutide vs Cotadutide

Survodutide and Cotadutide are investigational dual glucagon/GLP-1 receptor agonists, but they occupy different positions in the research landscape. Survodutide, developed by Boehringer Ingelheim and Zealand Pharma, has advanced into Phase 3 trials for obesity and MASH, supported by compelling Phase 2 data. Cotadutide (MEDI0382), from AstraZeneca, completed Phase 2 trials in type 2 diabetes, obesity, and NASH/MASH, but its development trajectory remains uncertain after mixed results and portfolio reprioritization. Both peptides combine glucagon-mediated hepatic fat oxidation and energy expenditure with GLP-1-driven appetite suppression and glucose regulation. However, Survodutide’s more advanced clinical pipeline and higher reported MASH resolution rates contrast with Cotadutide’s earlier-stage evidence and less definitive outcomes. Researchers should weigh these differences when designing studies focused on metabolic disease or hepatic steatosis.

Survodutide is a once-weekly injectable dual agonist of the glucagon and GLP-1 receptors, distinguishing it from tirzepatide’s GIP/GLP-1 mechanism. The glucagon component enhances hepatic fat oxidation and energy expenditure, complementing GLP-1-mediated appetite suppression and delayed gastric emptying. In a Phase 2 trial for MASH, survodutide achieved MASH resolution without worsening fibrosis in 83% of patients at the highest dose, a notably high rate compared to historical controls. The peptide also produced significant weight loss and reductions in liver fat content, as measured by MRI-PDFF. These results have propelled survodutide into Phase 3 trials for both obesity and MASH, with ongoing studies evaluating long-term safety and efficacy. The evidence base for survodutide is thus relatively mature for a dual glucagon/GLP-1 agonist, with robust dose-ranging data and a clear path to regulatory evaluation. Researchers should note that the glucagon agonism may also increase heart rate, a class effect requiring monitoring in preclinical and clinical models.

Cotadutide (MEDI0382) is a once-daily dual GLP-1/glucagon receptor agonist designed to balance glycemic control, weight loss, and hepatic fat reduction. Its mechanism mirrors survodutide’s in combining GLP-1-mediated appetite suppression and glucose-dependent insulin secretion with glucagon-driven hepatic lipid oxidation. Phase 2 trials in type 2 diabetes and obesity demonstrated dose-dependent reductions in body weight and HbA1c, as well as decreases in liver fat content in patients with NASH/MASH. However, results were mixed: some studies showed modest efficacy relative to placebo, and gastrointestinal tolerability issues were prominent, particularly with once-daily dosing leading to peak-trough fluctuations. AstraZeneca’s decision to deprioritize cotadutide after Phase 2 has left its development status uncertain, and no Phase 3 trials are currently registered. For researchers, cotadutide remains a useful tool for studying dual agonist mechanisms in preclinical models, but its clinical evidence is less definitive than survodutide’s. The once-daily regimen may also inform studies on dosing frequency and tolerability.

Both survodutide and cotadutide are primarily investigated for weight management and metabolic health, including obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD)/MASH. Their dual agonism of glucagon and GLP-1 receptors positions them as tools to study the interplay between appetite regulation, energy expenditure, and hepatic lipid metabolism. Survodutide has also been explicitly studied for MASH resolution, with Phase 2 data showing high rates of histological improvement. Cotadutide, while similarly applied to NASH/MASH, has not demonstrated the same magnitude of effect in published trials. Neither peptide has been reported for unique applications beyond these metabolic and hepatic indications. Researchers should consider that survodutide’s more advanced evidence may support translational studies aiming for clinical relevance, while cotadutide may be more suitable for mechanistic work exploring once-daily dosing effects or early-stage proof-of-concept experiments.

Both peptides share a safety profile typical of incretin-based therapies, with gastrointestinal adverse events—nausea, vomiting, diarrhea—being most common. For survodutide, dose-dependent tolerability requires careful titration, and heart rate increases have been observed as a class effect of glucagon agonism. Phase 2 data indicate that GI events are manageable with gradual dose escalation, but high doses may exacerbate tolerability issues. Cotadutide’s once-daily dosing may produce more pronounced GI side effects due to peak-trough fluctuations compared to weekly formulations, potentially impacting adherence in long-term studies. Both agents have shown decreased appetite as a common effect, which contributes to weight loss but may also raise concerns about nutritional status in vulnerable populations. Researchers should monitor for hepatic safety, as glucagon agonism can alter liver enzyme levels, though no significant hepatotoxicity has been reported in trials to date. Comprehensive safety evaluation in preclinical models should include cardiovascular and gastrointestinal endpoints.